Selected article for: "antiviral treatment and empirical antiviral treatment"

Author: Lilei Yu; Yongqing Tong; Gaigai Shen; Aisi Fu; Yanqiu Lai; Xiaoya Zhou; Yuan Yuan; Yuhong Wang; Yuchen Pan; Zhiyao Yu; Yan Li; Tiangang Liu; Hong Jiang
Title: Immunodepletion with Hypoxemia: A Potential High Risk Subtype of Coronavirus Disease 2019
  • Document date: 2020_3_6
  • ID: 5imbomop_19
    Snippet: Three male adult patients diagnosed with COVID-2019 pneumonia were admitted to Renmin Hospital of Wuhan University on January 31, February 1 and 6, 2020 (Patient 1, Patient 2, Patient 3, respectively). The mean age of these patients are 74.3 ± 8.1 years. Patient 1 had a medical history of prostatic hyperplasia and Patient 3 had chronic bronchitis, while Patient 2 reported no underlying historic medical conditions. From the collection of clinical.....
    Document: Three male adult patients diagnosed with COVID-2019 pneumonia were admitted to Renmin Hospital of Wuhan University on January 31, February 1 and 6, 2020 (Patient 1, Patient 2, Patient 3, respectively). The mean age of these patients are 74.3 ± 8.1 years. Patient 1 had a medical history of prostatic hyperplasia and Patient 3 had chronic bronchitis, while Patient 2 reported no underlying historic medical conditions. From the collection of clinical features, we found that all patients reported fever and dyspnea (Table 1) . Moreover, Patient 1 also had diarrhea, and Patient 3 had cough and myalgia/fatigue additionally. Laboratory findings show that C-reactive protein (CRP) were obviously increased in all patients, and decreased lymphocyte counts and increased procalcitonin were observed in Patient 2 and 3 (Table 1) . Additionally, Patient 2 also had elevated hypersensitive troponin I, creatine, and urea in serum, indicating myocardial injury and renal function damage. Patient 3 had increases in aspartate aminotransferase (ASL) and alanine aminotransferase (ALT) ( Table 1) , which indicate liver injury. During the hospitalization, all patients received empirical antiviral and antibiotic treatment (Table 1) . Patient 1 also experienced intravenous immunoglobulin therapy from day 11 of hospitalization (Table 1) . Notably, three patients died on day 24, 13, 12 of hospitalization, respectively.

    Search related documents:
    Co phrase search for related documents
    • adult patient and antibiotic antiviral treatment: 1
    • adult patient and chronic bronchitis: 1
    • adult patient and clinical feature: 1
    • adult patient and dyspnea fever: 1
    • adult patient and immunoglobulin therapy: 1
    • alanine aminotransferase and ALT alanine aminotransferase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • alanine aminotransferase and aspartate aminotransferase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • alanine aminotransferase and clinical feature: 1, 2
    • alanine aminotransferase and dyspnea fever: 1, 2, 3, 4, 5, 6, 7, 8
    • alanine aminotransferase and function damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • alanine aminotransferase and hypersensitive troponin: 1, 2, 3, 4, 5
    • ALT alanine aminotransferase and aspartate aminotransferase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ALT alanine aminotransferase and clinical feature: 1
    • ALT alanine aminotransferase and dyspnea fever: 1, 2
    • ALT alanine aminotransferase and function damage: 1, 2, 3, 4, 5, 6
    • ALT alanine aminotransferase and hypersensitive troponin: 1, 2, 3
    • antibiotic antiviral treatment and clinical feature: 1
    • antibiotic antiviral treatment and dyspnea fever: 1, 2
    • aspartate aminotransferase and clinical feature: 1, 2